Shih-Chun Hung
Papers
1
Total Citations
9
H-Index
1
About
Dr. Shih-Chun Hung is a distinguished urological researcher whose work centers on improving prostate cancer (PCa) diagnostics and prognostics. His primary research areas include the clinical utility of novel biomarkers, particularly the prostate health index (PHI) and its derivative, %p2PSA, for predicting aggressive disease. In his landmark 2020 study, Dr. Hung demonstrated that preoperative %p2PSA and PHI significantly enhance the accuracy of predicting adverse pathological outcomes—such as extraprostatic extension and seminal vesicle invasion—in patients undergoing radical prostatectomy. This work, which has garnered 9 citations, directly addresses the critical need for non-invasive tools to stratify risk and guide treatment decisions, potentially reducing overtreatment of indolent cancers. By validating these biomarkers in a cohort of 91 men with organ-confined PCa, Dr. Hung has contributed to a more personalized approach in urologic oncology. His research bridges the gap between serum-based tests and surgical pathology, offering clinicians a practical, pre-operative window into tumor aggressiveness. For students and researchers, Dr. Hung’s work exemplifies how translational studies can refine clinical decision-making and improve patient outcomes in prostate cancer care.
Research Focus
Key Achievements
Top Papers
- 1